ClinicalTrials.gg
CompletedNCT04707313Updated Nov 5, 2024Results posted

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

A Phase 2 interventional study of Placebo (Cohorts 1 and 2) and PF-06882961 (Cohorts 1 and 2) in Obesity, sponsored by Pfizer. Completed at 41 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.

Enrollment
14th of 62
628 · median 127
Started
2021
with 2 others
Phase 2
11 of 64
none open now
Registered
29th of 64
by date

Among the 64 studies in Obesity by Pfizer, this one is the 14th largest by enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2021, is one of 11 in phase 2, and was the 29th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Obesity by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a look- alike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight, waist and hip measurements, how well they tolerate the study medicine, and to measure levels of the study medicine in participants' blood.

This study is seeking participants who have obesity, who do not have diabetes and who have had a stable body weight and not participated in a formal weight loss program in the 90 days before the study. The study medicine or placebo will be taken as tablets by mouth 2 times a day (1 time in the morning and 1 time in the evening).

There are 3 groups of participants (called cohorts) in this study. For participants in Cohorts 1 and 2, total study participation will be about 9 months, with 15 planned study visits (14 visits to the study clinic and 1 telephone call). For participants in Cohort 3, total study participation will be about 10 months, with 21 planned study visits (12 visits to the study clinic and 9 telephone calls).

03

Conditions studied

  • Obesity

Keywords

  • Weight loss
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with obesity, defined as a greater than or equal to 30.0 kg/m2
  • Stable body weight, defined as \<5 kg change (per participant report) for 90 days before visit 1

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • Current or prior diagnosis of Type 1 or Type 2 diabetes mellitus or secondary forms of diabetes
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or within 6 months prior to visit 1
  • Any not considered cured
  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 or suspected MTC
  • History of acute pancreatitis within 180 days (6 months) prior to visit 1 or any history of chronic pancreatitis
  • Symptomatic gallbladder disease
  • Medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders
  • History of major depressive disorder or other severe psychiatric disorders within the last 2 years
  • Any lifetime history of a suicide attempt
  • Known medical history of active liver disease, including chronic active or C, or primary biliary cirrhosis
  • Known history of
  • Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
  • abnormalities
  • Positive urine drug screen
  • Participation in a formal weight reduction program within 90 days prior to visit 1
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
628 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Cohorts 1 and 2)

    Drug: Placebo (Cohorts 1 and 2)

  • Experimental
    PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1)

    The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Experimental
    PF-06882961 80 mg BID, 1-week titration (Cohort 1)

    The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Experimental
    PF-06882961 120 mg BID, 1-week titration (Cohort 1)

    The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Experimental
    PF-06882961 160 mg BID, 1-week titration (Cohort 1)

    The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Experimental
    PF-06882961 200 mg BID, 1-week titration (Cohort 1)

    The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Experimental
    PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2)

    The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Experimental
    PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2)

    The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Experimental
    PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2)

    The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID.

    Drug: PF-06882961 (Cohorts 1 and 2)

  • Placebo comparator
    Placebo (Cohort 3)

    Drug: Placebo (Cohort 3)

  • Experimental
    PF-06882961 80 mg BID, 4-week titration (Cohort 3)

    The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 80 mg BID.

    Drug: PF-06882961 (Cohort 3)

  • Experimental
    PF-06882961 140 mg BID, 4-week titration (Cohort 3)

    The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 140 mg BID.

    Drug: PF-06882961 (Cohort 3)

  • Experimental
    PF-06882961 200 mg BID, 4-week titration (Cohort 3)

    The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 200 mg BID.

    Drug: PF-06882961 (Cohort 3)

Interventions

  • DrugPlacebo (Cohorts 1 and 2)

    4 matching placebo tablets taken twice daily

  • DrugPF-06882961 (Cohorts 1 and 2)

    Drug page: Danuglipron

    Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily

  • DrugPlacebo (Cohort 3)

    2 matching placebo tablets taken twice daily

  • Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.

06

What researchers measure

Primary outcomes

  1. Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26

    Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100 multiply by \[\*\](back-transformed LS Mean minus \[-\] 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Week 26

  2. Cohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 32

    Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Week 32

Secondary outcomes

  1. Cohorts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus follow-up period).

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to 31 weeks)

  2. Cohort 3: Number of Participants With TEAEs and TESAEs

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus lag time).

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to 37 weeks)

  3. Cohorts 1 and 2: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality

    Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)

  4. Cohort 3: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality

    Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)

  5. Cohorts 1 and 2: Number of Participants According to Categorization of Vital Signs Data

    Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)

  6. Cohort 3: Number of Participants According to Categorization of Vital Signs Data

    Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)

  7. Cohorts 1 and 2: Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters

    Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)

  8. Cohort 3: Number of Participants According to Categorization of ECG Parameters

    Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.

    Time frame: From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)

  9. Cohorts 1 and 2: Number of Participants With Categorical Scores on Columbia-Suicide Severity Rating Scale (C-SSRS) Leading to Study Discontinuation

    C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

    Time frame: Week 0 (Baseline), 2, 4, 6, 8, 10, 12, 16, 18, 22, 26, Follow-up (Week 31)

  10. Cohort 3: Number of Participants With Categorical Scores on C-SSRS Leading to Study Discontinuation

    C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

    Time frame: Week 0 (Baseline), 4, 8, 12, 16, 20, 24, 28, 32, Follow-up (Week 37)

  11. Cohort 1 and 2: Number of Participants With Scores on the Patient Health Questionnaire-9 (PHQ-9) Leading to Study Discontinuation

    PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

    Time frame: Week 0 (Baseline) , 2, 4, 6, 8, 10, 12, 16, 18, 22, 26, Follow-up (Week 31)

  12. Cohort 3: Number of Participants With Scores on the PHQ-9 Leading to Study Discontinuation

    PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

    Time frame: Week 0 (Baseline), 4, 8, 12, 16, 20, 24, 28, 32, Follow-up (Week 37)

  13. Cohorts 1 and 2: Number of Participants With >= 5% Body Weight Loss at End of Treatment

    Number of participants with \>= 5% body weight loss at end of treatment were reported.

    Time frame: Week 26

  14. Cohort 3: Number of Participants With >=5% Body Weight Loss at End of Treatment

    Number of participants with \>= 5% body weight loss at end of treatment were reported.

    Time frame: Week 32

  15. Cohorts 1 and 2: Percent Change From Baseline in Body Weight at Weeks 2, 4, 6, 8, 10, 12,16, 18, 22

    Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12,16, 18, 22

  16. Cohort 3: Percent Change From Baseline in Body Weight at Weeks 4, 8, 12, 16, 20, 24 and 28

    Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24 and 28

  17. Cohorts 1 and 2: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 26

    Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Week 26

  18. Cohort 3: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 32

    Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Week 32

  19. Cohorts 1 and 2: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 26

    Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Week 26

  20. Cohort 3: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 32

    Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Week 32

  21. Cohorts 1 and 2: Absolute Change From Baseline in Percentage Hemoglobin A1c (HbA1c) at Weeks 16 and 26

    Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Weeks 16 and 26

  22. Cohort 3: Absolute Change From Baseline in Percentage HbA1c at Weeks 16, 24 and 32

    Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Weeks 16, 24 and 32

  23. Cohorts 1 and 2: Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 2, 4, 6, 8, 10, 12, 16, 18, 22, 26

    Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 16, 18, 22, 26

  24. Cohort 3: Absolute Change From Baseline in FPG at Weeks 4, 8, 12, 16, 20, 24, 28, 32

    Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32

07

Results

Posted Oct 9, 2024

Participant flow

Cohorts 1 and 2(Week 1 - Week 26)
Participant flow — Cohorts 1 and 2(Week 1 - Week 26)
MilestoneCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Started7162646438633764360000
Received treatment7162636438633763360000
Completed4427302613181114130000
Not completed2735343825452650230000
Withdrew: Adverse event420232515381542160000
Withdrew: Lack of efficacy5100100000000
Withdrew: Lost to follow-up5445323220000
Withdrew: Non-compliance with study drug0120100000000
Withdrew: Other1411200010000
Withdrew: Protocol violation1000012100000
Withdrew: Withdrawal by subject11537346440000
Withdrew: Randomized not treated0010000100000
Cohort 3 (Week 0 to Week 32)
Participant flow — Cohort 3 (Week 0 to Week 32)
MilestoneCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Started00000000019373736
Received treatment00000000019373736
Completed00000000011131511
Not completed0000000008242225
Withdrew: Adverse event000000000091618
Withdrew: Lack of efficacy0000000003110
Withdrew: Lost to follow-up0000000003523
Withdrew: Other0000000000101
Withdrew: Protocol violation0000000001100
Withdrew: Withdrawal by subject0000000001733

Outcome measures

PrimaryCohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26

Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100 multiply by \[\*\](back-transformed LS Mean minus \[-\] 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percent change
Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26
Percent changeCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 260.17 ± 0.008-5.43 ± 0.009-4.83 ± 0.009-8.94 ± 0.009-6.43 ± 0.012-9.36 ± 0.010-6.96 ± 0.013-8.96 ± 0.011-7.02 ± 0.012
Statistical analysis
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 40mg BID (1-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -5.60 · 90% CI -7.41 to -3.74MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 80mg BID (1-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -5.00 · 90% CI -6.80 to -3.16MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 120mg BID (1-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -9.10 · 90% CI -10.89 to -7.28MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -6.60 · 90% CI -8.75 to -4.39MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohort 1: PF-06882961 160 mg BID (1-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -9.52 · 90% CI -11.43 to -7.56MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -7.12 · 90% CI -9.41 to -4.78MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohort 1: PF-06882961 200 mg BID (1-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -9.12 · 90% CI -11.11 to -7.08MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -7.18 · 90% CI -9.32 to -4.99MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
PrimaryCohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 32

Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Week 32
Reported as:
Least squares mean · Percent change
Cohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 32
Percent changeCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Cohort 3: Percent Change From Baseline in Body Weight at End of Treatment at Week 321.40 ± 0.018-6.92 ± 0.014-7.15 ± 0.014-11.65 ± 0.014
Statistical analysis
  • Cohort 3: Placebo vs Cohort 3: PF-06882961 80mg BID (4-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -8.21 · 90% CI -11.66 to -4.63MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohort 3: Placebo vs Cohort 3: PF-06882961 140mg BID (4-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -8.44 · 90% CI -11.83 to -4.92MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
  • Cohort 3: Placebo vs Cohort 3: PF-06882961 200mg BID (4-week Titration) · Mixed Models Analysis · p = <.0001 · Difference to placebo: -12.87 · 90% CI -16.15 to -9.47MMRM:treatment,time,strata(female vs male),treatment-by-time interaction as fixed effect, natural log-transformed baseline as covariate,natural log-transformed baseline-by-time interaction with time fitted:repeated effect, participant:random effect.
SecondaryCohorts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus follow-up period).

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to 31 weeks)
Reported as:
Count of participants · Participants
Cohorts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)
ParticipantsCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
TEAEs505259543259305930
TESAEs121011051
SecondaryCohort 3: Number of Participants With TEAEs and TESAEs

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose met one or more of the criteria such as resulted in death; life threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent disability or incapacity, congenital anomaly or birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. An adverse event is considered treatment-emergent relative to given treatment if the event starts during the effective duration of the treatment (i.e. starting on or after the first dose but before the last dose plus lag time).

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to 37 weeks)
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants With TEAEs and TESAEs
ParticipantsCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
TEAEs13303434
TESAEs0223
SecondaryCohorts 1 and 2: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality

Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)
Reported as:
Count of participants · Participants
Cohorts 1 and 2: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality
ParticipantsCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Cohorts 1 and 2: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality665660573754335933
SecondaryCohort 3: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality

Laboratory parameters:a)hematology:hemoglobin(Hg),hematocrit,erythrocytes(ery),neutrophils,ery mean corpuscular volume,platelets,leukocytes(leu),lymphocytes,basophils,eosinophils,monocytes activated partial thromboplastin time, prothrombin time,prothrombin initial normalised ratio b)chemistry:direct bilirubin(bil),indirect bil, gamma glutamyl transferase,urea nitrogen,urate,sodium,potassium,calcium(cal),cal corrected,bicarbonate,Hg a1c,creatine kinase,bile acid,calcitonin,insulin-fasting,glucose fasting,amylase,lipase,thyrotropin,thyroxine,free,cholesterol,high density lipoprotein (hdl) cholesterol,triglycerides,alanine aminotransferase c)urinalysis:urine:pH,ketone,protein, Hg, urobilinogen,nitrite,leu esterase,ery,leu,tubular epithelial cells,squamous epithelial cells,granular casts,hyaline casts,uric acid crystals,calcium oxalate crystals,amorphous crystals,mucus,microscopic exam,spermatozoa,yeast budding,transitional epithelial cells,leu cell clumps;yeast hyphae.

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality
ParticipantsCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Cohort 3: Number of Participants With Laboratory Abnormalities, Without Regard to Baseline Abnormality15313432
SecondaryCohorts 1 and 2: Number of Participants According to Categorization of Vital Signs Data

Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)
Reported as:
Count of participants · Participants
Cohorts 1 and 2: Number of Participants According to Categorization of Vital Signs Data
ParticipantsCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
SBP Value < 90001012100
DBP Value < 50001000000
PR <40 beats per minute000000000
PR >120 beats per minute000000000
SecondaryCohort 3: Number of Participants According to Categorization of Vital Signs Data

Vital signs of systolic blood pressure, diastolic blood pressure and pulse rate and were measured using an automated device with the participant in a supine position after five minutes of rest. This reports the number of participants that met the following pre-specified criteria: systolic blood pressure (SBP) \<90 millimetres of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, pulse rate (PR) \<40 beats per minute, \>120 beats per minute.

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants According to Categorization of Vital Signs Data
ParticipantsCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
DBP Value < 500010
SBP Value < 900000
PR <40 beats per minute0000
PR >120 beats per minute0000
SecondaryCohorts 1 and 2: Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters

Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 31 weeks)
Reported as:
Count of participants · Participants
Cohorts 1 and 2: Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters
ParticipantsCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
QRS interval >=140001001000
QTCF interval >500000000000
PR interval >=300000000000
SecondaryCohort 3: Number of Participants According to Categorization of ECG Parameters

Standard 12-lead ECGs were measured with the participant in a supine position after at least five minutes of rest. This reports the number of participants that met the following pre-specified criteria for ECG: QRS interval \>=140; PR interval \>=300; QTCF interval \>500.

Time frame:
From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (up to 37 weeks)
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants According to Categorization of ECG Parameters
ParticipantsCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
QRS interval >=1400001
QTCF interval >5000000
PR interval >=3000000
SecondaryCohorts 1 and 2: Number of Participants With Categorical Scores on Columbia-Suicide Severity Rating Scale (C-SSRS) Leading to Study Discontinuation

C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

Time frame:
Week 0 (Baseline), 2, 4, 6, 8, 10, 12, 16, 18, 22, 26, Follow-up (Week 31)
Reported as:
Count of participants · Participants
Cohorts 1 and 2: Number of Participants With Categorical Scores on Columbia-Suicide Severity Rating Scale (C-SSRS) Leading to Study Discontinuation
ParticipantsCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Cohorts 1 and 2: Number of Participants With Categorical Scores on Columbia-Suicide Severity Rating Scale (C-SSRS) Leading to Study Discontinuation000000000
SecondaryCohort 3: Number of Participants With Categorical Scores on C-SSRS Leading to Study Discontinuation

C-SSRS is an interview-based rating scale to assess suicidal ideation and behavior. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

Time frame:
Week 0 (Baseline), 4, 8, 12, 16, 20, 24, 28, 32, Follow-up (Week 37)
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants With Categorical Scores on C-SSRS Leading to Study Discontinuation
ParticipantsCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Cohort 3: Number of Participants With Categorical Scores on C-SSRS Leading to Study Discontinuation0000
SecondaryCohort 1 and 2: Number of Participants With Scores on the Patient Health Questionnaire-9 (PHQ-9) Leading to Study Discontinuation

PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

Time frame:
Week 0 (Baseline) , 2, 4, 6, 8, 10, 12, 16, 18, 22, 26, Follow-up (Week 31)
Reported as:
Count of participants · Participants
Cohort 1 and 2: Number of Participants With Scores on the Patient Health Questionnaire-9 (PHQ-9) Leading to Study Discontinuation
ParticipantsCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Cohort 1 and 2: Number of Participants With Scores on the Patient Health Questionnaire-9 (PHQ-9) Leading to Study Discontinuation0 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
SecondaryCohort 3: Number of Participants With Scores on the PHQ-9 Leading to Study Discontinuation

PHQ-9 is a self-reported, nine-item scale for the assessment of depressive disorder. Per protocol, any participant with a pre-specified score was required to be evaluated by a mental health professional and, if meeting pre-defined criteria, discontinued from the study.

Time frame:
Week 0 (Baseline), 4, 8, 12, 16, 20, 24, 28, 32, Follow-up (Week 37)
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants With Scores on the PHQ-9 Leading to Study Discontinuation
ParticipantsCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Cohort 3: Number of Participants With Scores on the PHQ-9 Leading to Study Discontinuation0 ± 00 ± 00 ± 00 ± 0
SecondaryCohorts 1 and 2: Number of Participants With >= 5% Body Weight Loss at End of Treatment

Number of participants with \>= 5% body weight loss at end of treatment were reported.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Cohorts 1 and 2: Number of Participants With >= 5% Body Weight Loss at End of Treatment
ParticipantsCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Cohorts 1 and 2: Number of Participants With >= 5% Body Weight Loss at End of Treatment616151712156128
Statistical analysis
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 40mg BID (1-week Titration) · Odds ratio (or): 7.37 · 90% CI 2.81 to 19.30
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 80mg BID (1-week Titration) · Odds ratio (or): 6.58 · 90% CI 2.62 to 16.53
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 120mg BID (1-week Titration) · Odds ratio (or): 16.33 · 90% CI 6.47 to 41.24
  • Cohorts 1 and 2: Placebo vs Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration) · Odds ratio (or): 14.24 · 90% CI 5.39 to 37.66
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 160 mg BID (1-week Titration) · Odds ratio (or): 30.17 · 90% CI 11.35 to 80.20
  • Cohorts 1 and 2: Placebo vs Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration) · Odds ratio (or): 9.88 · 90% CI 2.91 to 33.53
  • Cohorts 1 and 2: Placebo vs Cohort 1: PF-06882961 200 mg BID (1-week Titration) · Odds ratio (or): 24.41 · 90% CI 8.28 to 71.95
  • Cohorts 1 and 2: Placebo vs Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration) · Odds ratio (or): 12.65 · 90% CI 4.56 to 35.08
SecondaryCohort 3: Number of Participants With >=5% Body Weight Loss at End of Treatment

Number of participants with \>= 5% body weight loss at end of treatment were reported.

Time frame:
Week 32
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants With >=5% Body Weight Loss at End of Treatment
ParticipantsCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Cohort 3: Number of Participants With >=5% Body Weight Loss at End of Treatment091110
Statistical analysis
  • Cohort 3: Placebo vs Cohort 3: PF-06882961 80mg BID (4-week Titration) · Odds ratio (or): 33.43 · 90% CI 3.05 to 366.64
  • Cohort 3: Placebo vs Cohort 3: PF-06882961 140mg BID (4-week Titration) · Odds ratio (or): 34.04 · 90% CI 3.10 to 373.85
  • Cohort 3: Placebo vs Cohort 3: PF-06882961 200mg BID (4-week Titration) · Odds ratio (or): 127.21 · 90% CI 10.55 to 1533.46
SecondaryCohorts 1 and 2: Percent Change From Baseline in Body Weight at Weeks 2, 4, 6, 8, 10, 12,16, 18, 22

Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, 12,16, 18, 22
Reported as:
Least squares mean · Percent Change
Cohorts 1 and 2: Percent Change From Baseline in Body Weight at Weeks 2, 4, 6, 8, 10, 12,16, 18, 22
Percent ChangeCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Week 2-0.13 ± 0.001-0.85 ± 0.001-0.54 ± 0.001-0.98 ± 0.001-0.58 ± 0.002-0.87 ± 0.001-0.22 ± 0.002-0.96 ± 0.001-0.53 ± 0.002
Week 4-0.15 ± 0.002-1.65 ± 0.002-1.69 ± 0.002-1.99 ± 0.002-1.26 ± 0.003-1.71 ± 0.002-0.93 ± 0.003-1.98 ± 0.002-1.28 ± 0.003
Week 6-0.24 ± 0.003-2.26 ± 0.003-2.37 ± 0.003-2.96 ± 0.003-1.99 ± 0.003-2.84 ± 0.003-1.93 ± 0.004-2.97 ± 0.003-1.99 ± 0.004
Week 8-0.41 ± 0.003-2.93 ± 0.003-2.86 ± 0.003-3.89 ± 0.003-3.33 ± 0.004-3.87 ± 0.004-2.34 ± 0.004-3.83 ± 0.004-2.94 ± 0.004
Week 10-0.50 ± 0.004-3.47 ± 0.004-3.33 ± 0.004-4.82 ± 0.004-3.92 ± 0.005-4.67 ± 0.004-3.20 ± 0.005-4.54 ± 0.004-3.83 ± 0.005
Week 12-0.44 ± 0.004-3.89 ± 0.005-3.88 ± 0.004-5.31 ± 0.005-4.49 ± 0.006-5.66 ± 0.005-3.98 ± 0.006-5.33 ± 0.005-4.34 ± 0.006
Week 16-0.40 ± 0.005-4.73 ± 0.006-4.01 ± 0.006-6.98 ± 0.006-5.49 ± 0.008-7.04 ± 0.007-5.15 ± 0.008-6.56 ± 0.007-5.18 ± 0.008
Week 18-0.50 ± 0.006-4.94 ± 0.006-4.68 ± 0.006-7.33 ± 0.007-6.33 ± 0.008-7.50 ± 0.007-5.57 ± 0.009-7.27 ± 0.007-5.80 ± 0.008
Week 22-0.18 ± 0.007-5.06 ± 0.008-5.00 ± 0.007-8.10 ± 0.008-6.43 ± 0.010-8.63 ± 0.009-6.57 ± 0.011-8.23 ± 0.009-6.60 ± 0.010
SecondaryCohort 3: Percent Change From Baseline in Body Weight at Weeks 4, 8, 12, 16, 20, 24 and 28

Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100\*(back-transformed LS Mean - 1). Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24 and 28
Reported as:
Least squares mean · Percent Change
Cohort 3: Percent Change From Baseline in Body Weight at Weeks 4, 8, 12, 16, 20, 24 and 28
Percent ChangeCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Week 4-0.37 ± 0.004-1.38 ± 0.003-0.95 ± 0.003-1.02 ± 0.003
Week 8-0.06 ± 0.006-2.07 ± 0.004-1.93 ± 0.004-1.89 ± 0.004
Week 12-0.08 ± 0.008-2.80 ± 0.006-2.88 ± 0.005-2.96 ± 0.006
Week 160.03 ± 0.011-4.13 ± 0.008-3.99 ± 0.007-4.73 ± 0.008
Week 200.38 ± 0.014-5.17 ± 0.010-5.25 ± 0.009-7.10 ± 0.010
Week 240.36 ± 0.015-5.65 ± 0.011-6.39 ± 0.011-9.20 ± 0.011
Week 281.06 ± 0.017-6.37 ± 0.013-6.74 ± 0.012-10.44 ± 0.013
SecondaryCohorts 1 and 2: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 26

Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Centimeter
Cohorts 1 and 2: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 26
CentimeterCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Cohorts 1 and 2: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 26-1.25 ± 0.826-6.49 ± 0.995-5.75 ± 0.943-6.19 ± 1.023-5.98 ± 1.338-9.05 ± 1.174-7.41 ± 1.490-7.56 ± 1.281-6.36 ± 1.350
SecondaryCohort 3: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 32

Absolute change from baseline in waist circumference were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Week 32
Reported as:
Least squares mean · Centimeter
Cohort 3: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 32
CentimeterCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Cohort 3: Absolute Change From Baseline in Waist Circumference at End of Treatment at Week 320.19 ± 1.967-6.27 ± 1.628-7.77 ± 1.564-11.43 ± 1.698
SecondaryCohorts 1 and 2: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 26

Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Ratio
Cohorts 1 and 2: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 26
RatioCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Cohorts 1 and 2: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 26-0.002 ± 0.0064-0.002 ± 0.0076-0.015 ± 0.00730.001 ± 0.0078-0.014 ± 0.0104-0.015 ± 0.0090-0.014 ± 0.0114-0.007 ± 0.00980.004 ± 0.0104
SecondaryCohort 3: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 32

Absolute change from baseline in waist-to-hip ratio at end of treatment were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Week 32
Reported as:
Least squares mean · Ratio
Cohort 3: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 32
RatioCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Cohort 3: Absolute Change From Baseline in Waist-to-hip Ratio at End of Treatment at Week 320.010 ± 0.0128-0.012 ± 0.0113-0.009 ± 0.0108-0.016 ± 0.0121
SecondaryCohorts 1 and 2: Absolute Change From Baseline in Percentage Hemoglobin A1c (HbA1c) at Weeks 16 and 26

Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Weeks 16 and 26
Reported as:
Least squares mean · Percentage of HbA1c
Cohorts 1 and 2: Absolute Change From Baseline in Percentage Hemoglobin A1c (HbA1c) at Weeks 16 and 26
Percentage of HbA1cCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Week 160.00 ± 0.034-0.24 ± 0.039-0.24 ± 0.039-0.26 ± 0.042-0.25 ± 0.056-0.29 ± 0.050-0.18 ± 0.061-0.23 ± 0.053-0.24 ± 0.054
Week 260.01 ± 0.036-0.17 ± 0.045-0.13 ± 0.044-0.22 ± 0.046-0.16 ± 0.064-0.31 ± 0.055-0.13 ± 0.070-0.17 ± 0.062-0.26 ± 0.064
SecondaryCohort 3: Absolute Change From Baseline in Percentage HbA1c at Weeks 16, 24 and 32

Absolute change from baseline in HbA1c were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Weeks 16, 24 and 32
Reported as:
Least squares mean · Percentage of HbA1c
Cohort 3: Absolute Change From Baseline in Percentage HbA1c at Weeks 16, 24 and 32
Percentage of HbA1cCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Week 16-0.05 ± 0.061-0.16 ± 0.048-0.26 ± 0.044-0.29 ± 0.042
Week 240.05 ± 0.070-0.13 ± 0.059-0.21 ± 0.055-0.31 ± 0.059
Week 32-0.02 ± 0.074-0.11 ± 0.064-0.27 ± 0.059-0.41 ± 0.068
SecondaryCohorts 1 and 2: Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 2, 4, 6, 8, 10, 12, 16, 18, 22, 26

Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, 12, 16, 18, 22, 26
Reported as:
Least squares mean · Milligram per deciliter
Cohorts 1 and 2: Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 2, 4, 6, 8, 10, 12, 16, 18, 22, 26
Milligram per deciliterCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)
Week 23.22 ± 0.903-2.93 ± 0.963-2.56 ± 0.939-4.02 ± 0.940-2.02 ± 1.245-4.51 ± 0.957-1.16 ± 1.265-2.82 ± 0.939-2.93 ± 1.250
Week 43.38 ± 1.082-2.75 ± 1.196-2.97 ± 1.166-3.59 ± 1.155-0.83 ± 1.443-4.81 ± 1.199-2.56 ± 1.504-6.24 ± 1.164-3.86 ± 1.485
Week 61.45 ± 0.936-4.28 ± 1.021-2.29 ± 1.035-6.38 ± 1.044-4.17 ± 1.290-3.46 ± 1.102-3.06 ± 1.371-4.32 ± 1.095-4.64 ± 1.311
Week 81.61 ± 0.956-3.72 ± 1.068-3.15 ± 1.103-2.56 ± 1.130-2.77 ± 1.385-4.48 ± 1.177-4.07 ± 1.438-4.90 ± 1.248-2.82 ± 1.367
Week 102.47 ± 1.146-2.52 ± 1.264-1.79 ± 1.251-4.74 ± 1.353-2.60 ± 1.662-4.17 ± 1.498-5.26 ± 1.702-5.35 ± 1.525-2.85 ± 1.558
Week 122.57 ± 1.229-2.70 ± 1.408-0.77 ± 1.377-2.24 ± 1.492-1.22 ± 1.889-4.86 ± 1.686-4.65 ± 1.908-3.01 ± 1.716-3.19 ± 1.764
Week 160.50 ± 1.352-2.67 ± 1.523-2.04 ± 1.537-2.56 ± 1.619-6.99 ± 2.143-6.62 ± 1.926-5.73 ± 2.338-4.67 ± 2.011-5.24 ± 2.097
Week 184.34 ± 1.407-0.44 ± 1.634-3.73 ± 1.5930.19 ± 1.770-0.96 ± 2.294-4.76 ± 2.030-5.23 ± 2.6840.11 ± 2.1750.53 ± 2.189
Week 224.83 ± 1.4940.38 ± 1.872-3.22 ± 1.712-4.27 ± 1.842-1.78 ± 2.502-2.03 ± 2.205-1.65 ± 2.888-4.64 ± 2.460-5.08 ± 2.580
Week 263.34 ± 1.220-3.37 ± 1.499-3.43 ± 1.469-4.02 ± 1.555-3.75 ± 2.059-6.00 ± 1.804-3.50 ± 2.290-6.60 ± 2.010-5.01 ± 2.172
SecondaryCohort 3: Absolute Change From Baseline in FPG at Weeks 4, 8, 12, 16, 20, 24, 28, 32

Absolute change from baseline in FPG were reported. Analysis was performed using MMRM model with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. Baseline was defined as the average of the duplicate measurements collected closest prior to dosing at Day 1.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Least squares mean · Milligram per deciliter
Cohort 3: Absolute Change From Baseline in FPG at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Milligram per deciliterCohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
Week 4-1.82 ± 2.327-0.83 ± 1.6520.96 ± 1.6163.84 ± 1.671
Week 80.10 ± 2.5231.79 ± 1.748-1.16 ± 1.6592.52 ± 1.720
Week 12-1.28 ± 2.588-1.80 ± 1.8831.56 ± 1.755-0.42 ± 1.761
Week 16-5.75 ± 2.348-5.18 ± 1.778-2.43 ± 1.6540.88 ± 1.618
Week 201.52 ± 2.175-1.95 ± 1.774-4.78 ± 1.687-1.39 ± 1.628
Week 24-2.80 ± 2.664-0.13 ± 2.088-2.00 ± 2.0141.62 ± 2.158
Week 281.67 ± 2.518-0.15 ± 2.044-4.53 ± 1.9830.90 ± 2.221
Week 32-1.81 ± 3.0061.28 ± 2.491-1.65 ± 2.446-1.73 ± 2.582

Adverse events

Collected over From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment (maximum up to Week 31 for Cohort 1 and 2; maximum up to Week 37 for Cohort 3). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohorts 1 and 2: Placebo0/71 (0%)1/71 (1.4%)29/71 (40.8%)
Cohort 1: PF-06882961 40 mg BID (1-week Titration)0/62 (0%)2/62 (3.2%)46/62 (74.2%)
Cohort 1: PF-06882961 80mg BID (1-week Titration)0/63 (0%)1/63 (1.6%)53/63 (84.1%)
Cohort 1: PF-06882961 120mg BID (1-week Titration)0/64 (0%)0/64 (0%)51/64 (79.7%)
Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)0/38 (0%)1/38 (2.6%)31/38 (81.6%)
Cohort 1: PF-06882961 160 mg BID (1-week Titration)0/63 (0%)1/63 (1.6%)56/63 (88.9%)
Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)0/37 (0%)0/37 (0%)29/37 (78.4%)
Cohort 1: PF-06882961 200 mg BID (1-week Titration)0/63 (0%)5/63 (7.9%)56/63 (88.9%)
Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)0/36 (0%)1/36 (2.8%)26/36 (72.2%)
Cohort 3: Placebo0/19 (0%)0/19 (0%)13/19 (68.4%)
Cohort 3: PF-06882961 80mg BID (4-week Titration)0/37 (0%)2/37 (5.4%)28/37 (75.7%)
Cohort 3: PF-06882961 140mg BID (4-week Titration)0/37 (0%)2/37 (5.4%)33/37 (89.2%)
Cohort 3: PF-06882961 200mg BID (4-week Titration)0/36 (0%)3/36 (8.3%)34/36 (94.4%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
COVID-19Infections and infestations0/710/620/630/640/380/630/370/631/360/190/370/370/36
Bundle branch block leftCardiac disorders0/710/620/630/640/380/630/370/630/360/190/370/371/36
NauseaGastrointestinal disorders0/710/620/630/640/380/630/370/630/360/190/370/371/36
VomitingGastrointestinal disorders0/710/620/630/640/380/630/370/630/360/190/370/371/36
Pharyngitis streptococcalInfections and infestations0/710/620/630/640/380/630/370/630/360/190/370/371/36
Aortic valve stenosisCardiac disorders0/710/620/630/640/380/630/370/630/360/190/371/370/36
Atrial fibrillationCardiac disorders0/710/620/630/640/380/630/370/630/360/190/371/370/36
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/710/620/630/640/380/630/370/630/360/191/370/370/36
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/710/620/630/640/380/630/370/630/360/191/370/370/36
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/710/620/630/640/380/630/370/630/360/190/371/370/36
Most frequent other events
Showing 10 of 61
Most frequent other events
EventCohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)
NauseaGastrointestinal disorders11/7128/6239/6341/6422/3836/6325/3734/6318/362/1914/3727/3725/36
VomitingGastrointestinal disorders2/7110/6224/6326/6416/3827/6311/3729/6316/361/193/3714/3717/36
DiarrhoeaGastrointestinal disorders7/715/6217/6312/649/3813/633/3711/636/361/198/378/379/36
Gastrooesophageal reflux diseaseGastrointestinal disorders0/717/628/638/6410/383/634/3710/636/361/192/372/378/36
DyspepsiaGastrointestinal disorders1/716/6211/635/645/3813/632/3713/634/361/195/373/377/36
ConstipationGastrointestinal disorders3/718/6210/637/645/3812/634/379/636/362/197/372/375/36
HeadacheNervous system disorders8/716/6211/6311/643/3811/636/377/636/363/195/373/374/36
Urinary tract infectionInfections and infestations3/714/628/634/641/383/630/374/632/360/194/373/375/36
FatigueGeneral disorders5/713/624/637/640/386/635/377/632/361/195/371/371/36
Abdominal distensionGastrointestinal disorders1/713/623/633/645/382/633/372/630/361/192/371/371/36

Baseline characteristics

Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.

Age, Customized
Age, Customized(Participants)Cohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)Total
18-44 years2827262114221725118121314238
45-64 years3431303617342031209242419329
Greater than or equal to (>=)65 years947777075210359
Sex: Female, Male
Sex: Female, Male(Participants)Cohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)Total
Female45404142224122412312232322397
Male2622222216221522137141414229
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)Total
Hispanic or Latino678732425023251
Not Hispanic or Latino65555456346133603019343434569
Unknown or Not Reported00111001101006
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohorts 1 and 2: PlaceboCohort 1: PF-06882961 40 mg BID (1-week Titration)Cohort 1: PF-06882961 80mg BID (1-week Titration)Cohort 1: PF-06882961 120mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 120 mg BID (2-week Titration)Cohort 1: PF-06882961 160 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 160 mg BID (2-week Titration)Cohort 1: PF-06882961 200 mg BID (1-week Titration)Cohorts 1 and 2: PF-06882961 200 mg BID (2-week Titration)Cohort 3: PlaceboCohort 3: PF-06882961 80mg BID (4-week Titration)Cohort 3: PF-06882961 140mg BID (4-week Titration)Cohort 3: PF-06882961 200mg BID (4-week Titration)Total
American Indian or Alaska Native00100100000024
Asian1181083102132000067
Native Hawaiian or Other Pacific Islander01000000000001
Black or African American44101148553386576
White55484245314230453116293128473
More than one race01000200000003
Unknown or Not Reported10000000000012
08

Study locations

41 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Velocity Clinical Research - Westlake
    Los Angeles, California 90057, United States
  • Alliance for Multispecialty Research, LLC
    Coral Gables, Florida 33134, United States
  • Optimus U Corporation
    Miami, Florida 33125, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Clinical Investigation Specialists
    Gurnee, Illinois 60031, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Velocity Clinical Research, Valparaiso
    Valparaiso, Indiana 46383, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • ActivMed Practices & Research, LLC
    Methuen, Massachusetts 01844, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28601, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • PMG Research of Salisbury, LLC
    Salisbury, North Carolina 28144, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Velocity Clinical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Clinical Trials of South Carolina
    Moncks Corner, South Carolina 29461, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Palmetto Primary Care Physicians (Sub-I physicals only)
    Summerville, South Carolina 29485, United States
  • Internal Medicine and Pediatric Associates of Bristol, PC
    Bristol, Tennessee 37620, United States
  • PMG Research, Inc. d/b/a PMG Research of Knoxville
    Knoxville, Tennessee 37938, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Rivergrove Medical Clinic
    Winnipeg, Manitoba R2V 4W3, Canada
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T 0G1, Canada
  • Milestone Research , Inc
    London, Ontario N5W 6A2, Canada
  • Manna Research Toronto
    Toronto, Ontario M9W 4L6, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Centre de Recherche Saint-Louis
    Quebec, G1W4R4, Canada
  • Alpha Recherche Clinique
    Quebec, G2J 0C4, Canada
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • Tokyo Center Clinic
    Chuo-ku, Tokyo 103-0028, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Medical Corporation Heishinkai ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • China Medical University Hospital
    Taichung City, 40447, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Sep 2023, 31 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 31 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2021
First posted
Jan 13, 2021
StartActual
Jan 29, 2021
Primary completionActual
Sep 13, 2023
CompletionActual
Oct 11, 2023
Results first posted
Oct 9, 2024
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04707313
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Jan 29, 2021
Primary completion
Sep 13, 2023
Completion
Oct 11, 2023
Results posted
Oct 9, 2024
Last update
Nov 5, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion